Lidokain/Adrenalin Aguettant

Lidocaine Hydrochloride and Epinephrine, the active ingredient in Lidokain/Adrenalin Aguettant, is a local anesthetic and vasoconstrictor presented as a sterile solution for injection for epidural, infiltration, intravenous and perineural use. It provides rapid onset anesthesia and prolongs effect by reducing local blood flow, making it suitable for minor surgical procedures and regional blocks.

GNH USA supplies Lidokain/Adrenalin Aguettant as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Lidokain/Adrenalin Aguettant, a combination local anesthetic and vasoconstrictor, is employed in procedures that require regional or infiltration anesthesia.

- Minor surgical procedures: provides local anesthesia and reduces intra‑operative bleeding. - Infiltration anesthesia: enables targeted numbness of tissue during minor interventions. - Epidural anesthesia: extends duration of analgesia for labor or surgical procedures. - Perineural (regional) anesthesia: facilitates nerve block for limb surgeries.

Adverse reactions may occur following administration of the combination solution.

Common Side Effects: - Transient pain or burning at the injection site - Tachycardia - Hypertension - Nausea - Light‑headedness - Localized swelling

Serious or Rare Side Effects: - Anaphylactic reaction - Severe cardiac arrhythmia - Seizure activity - Methemoglobinemia - Persistent hypotension - Respiratory depression

Careful assessment and monitoring are required when using this anesthetic combination.

- Allergy assessment: verify no known hypersensitivity to lidocaine or epinephrine. - Cardiovascular status: avoid in patients with uncontrolled hypertension, arrhythmias, or severe coronary disease. - Dosage limits: adhere to recommended maximum lidocaine dose to prevent systemic toxicity. - Pregnancy: use only if potential benefit justifies potential risk to the fetus. - Drug interactions: review concomitant medications for possible additive cardiovascular effects. - Store at ambient temperature: keep in original container, protect from light and moisture.

Lidokain/Adrenalin Aguettant may interact with several drug classes; monitoring is essential.

Major Interactions (Avoid): - Beta‑blockers: may potentiate hypertension and tachycardia. - Monoamine oxidase inhibitors (MAOIs): increase risk of hypertensive crisis. - Tricyclic antidepressants: may enhance cardiotoxicity of lidocaine.

Moderate Interactions (Monitor Closely): - Other local anesthetics: risk of cumulative systemic toxicity. - Diuretics: may alter plasma lidocaine concentrations. - Calcium channel blockers: may modify cardiovascular response to epinephrine.